Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

abstract：:RBM4 inhibits cancer cell growth and migration by regulating cancer-associated gene splicing. ...

journal_title：Cancer discovery

authors：

更新日期：2014-11-01 00:00:00

abstract：:Preliminary findings from a recent study suggest that combining intermittent fasting or a fasting-mimicking diet with endocrine therapy for hormone receptor-positive breast cancer may improve treatment efficacy and reduce side effects. ...

journal_title：Cancer discovery

authors：

更新日期：2020-11-01 00:00:00

abstract：:Recent results suggest that tucatinib, when combined with trastuzumab and capecitabine, is effective in patients with locally advanced inoperable or metastatic HER2-positive breast cancer who have received prior therapies: In a phase II trial, the drug extended overall survival and progression-free survival compared w...

journal_title：Cancer discovery

authors：

更新日期：2020-01-01 00:00:00

abstract：:In the large international phase III MAVORIC trial, patients with previously treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody mogamulizumab experienced significantly longer progression-free survival and higher response rates, as well as better quality of life, than those who received vo...

journal_title：Cancer discovery

authors：

更新日期：2018-02-01 00:00:00

abstract：:Findings from a phase I/IIa study indicate that combining the investigational indoleamine 2,3-dioxygenase 1 inhibitor BMS-986205 with nivolumab is safe and boosts response rates among patients with bladder and cervical cancers. ...

journal_title：Cancer discovery

authors：

更新日期：2018-01-01 00:00:00

abstract：:The ability of mitochondrial complex III to oxidize ubiquinol was essential to tumor growth in vivo. ...

journal_title：Cancer discovery

authors：

更新日期：2020-09-01 00:00:00

abstract：:53BP1 requires RIF1 to block 5' end resection required for homologous recombination. ...

journal_title：Cancer discovery

authors：

更新日期：2013-03-01 00:00:00

abstract：:Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease. Because of its heterogeneity and lack of hormone receptors or HER2 expression, targeted therapy is limited. Here, by performing a functional siRNA screening for 2-OG-dependent enzymes, we identified gamma-butyrobetaine hydroxylase 1 (BBOX...

journal_title：Cancer discovery

authors： Liao C,Zhang Y,Fan C,Herring LE,Liu J,Locasale JW,Takada M,Zhou J,Zurlo G,Hu L,Simon JM,Ptacek TS,Andrianov VG,Loza E,Peng Y,Yang H,Perou CM,Zhang Q

更新日期：2020-11-01 00:00:00

abstract：UNLABELLED:ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. ...

journal_title：Cancer discovery

authors： Shen J,Peng Y,Wei L,Zhang W,Yang L,Lan L,Kapoor P,Ju Z,Mo Q,Shih IeM,Uray IP,Wu X,Brown PH,Shen X,Mills GB,Peng G

更新日期：2015-07-01 00:00:00

abstract：:Ubiquitin-specific protease 2a, a deubiquitinating enzyme, elevates MYC levels in prostate cancer cells via its stabilization of MDM2, undermining p53 regulation of microRNAs that target MYC mRNA. ...

journal_title：Cancer discovery

authors： Nelson WG,De Marzo AM,Yegnasubramanian S

更新日期：2012-03-01 00:00:00

abstract：UNLABELLED:Glioblastomas (GBM) with EGFR amplification represent approximately 50% of newly diagnosed cases, and recent studies have revealed frequent coexistence of multiple EGFR aberrations within the same tumor, which has implications for mutation cooperation and treatment resistance. However, bulk tumor sequencing ...

journal_title：Cancer discovery

authors： Francis JM,Zhang CZ,Maire CL,Jung J,Manzo VE,Adalsteinsson VA,Homer H,Haidar S,Blumenstiel B,Pedamallu CS,Ligon AH,Love JC,Meyerson M,Ligon KL

更新日期：2014-08-01 00:00:00

abstract：:A multidisciplinary panel of experts has issued guidelines that consolidate current evidence on testing for molecular biomarkers in colorectal cancer. The guidelines aim to standardize molecular testing for patients with colorectal cancer and help clinicians identify patients most likely to benefit from targeted treat...

journal_title：Cancer discovery

authors：

更新日期：2017-04-01 00:00:00

abstract：:The California Institute of Quantitative Biosciences offers incubators and other programs that aim to close the gap between discovery and commercialization in biotechnology. ...

journal_title：Cancer discovery

authors：

更新日期：2012-12-01 00:00:00

abstract：:Pemigatinib was effective in patients with cholangiocarcinomas with FGFR2 fusions or rearrangements. ...

journal_title：Cancer discovery

authors：

更新日期：2020-05-01 00:00:00

abstract：:A new nanoparticle design may make cancer detection possible without the use of molecular markers of tumor cells. The star-shaped probe detected five different cancers in mouse models, according to a new study. By using nanostars to boost surface-enhanced resonance Raman scattering signals, the technique highlighted t...

journal_title：Cancer discovery

authors：

更新日期：2015-04-01 00:00:00

abstract：:In a first-in-human trial of an anti-CD22 chimeric antigen receptor T-cell therapy in children and young adults with relapsed and refractory acute lymphocytic leukemia, researchers found that the immunotherapeutic approach was not only feasible and safe, but also effective, leading to remissions in most patients. Infu...

journal_title：Cancer discovery

authors：

更新日期：2017-02-01 00:00:00

abstract：:Identifying the cancer cells-of-origin is of great interest, as it holds the potential to elucidate biologic mechanisms inherent in the normal cell state that have been co-opted to drive the oncogenic cell state. An emerging concept, proposed here, states that cancer stem cells, key players in cancer initiation and me...

journal_title：Cancer discovery

authors： Chaffer CL,Weinberg RA

更新日期：2015-01-01 00:00:00

abstract：:Researchers identified a small molecule that stimulates the production of stem cells in umbilical cord blood, potentially expanding treatment options for adults with hematologic cancers. ...

journal_title：Cancer discovery

authors：

更新日期：2014-12-01 00:00:00

abstract：:Preconditioning the immune system with a tetanus/diphtheria toxoid significantly improved the effectiveness of dendritic cell immunotherapy and extended overall survival in a small, randomized study of patients with glioblastoma. ...

journal_title：Cancer discovery

authors：

更新日期：2015-06-01 00:00:00

abstract：:The U.S. Preventive Services Task Force released new guidelines recommending BRCA mutation testing be limited to high-risk women who have received genetic counseling. ...

journal_title：Cancer discovery

authors：

更新日期：2014-02-01 00:00:00

abstract：:Celgene acquired Juno Therapeutics for $9 billion and is spending up to $7 billion on Impact Biomedicines in an effort to diversify its hematology portfolio with chimeric antigen receptor T-cell therapies and a JAK2 inhibitor before its best seller, lenalidomide, faces competition from generics. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:The structure of the chromatin-remodeling BAF complex provides molecular-scale mechanistic insight. ...

journal_title：Cancer discovery

authors：

更新日期：2020-03-01 00:00:00

abstract：:Amid concerns over the spread of COVID-19, oncology practices have "gone virtual," with video appointments scheduled for any service that does not require diagnostic testing or treatment. ...

journal_title：Cancer discovery

authors：

更新日期：2020-06-01 00:00:00

abstract：:In this issue of Cancer Discovery, Diab and colleagues demonstrate in a phase I trial enrolling 38 patients diagnosed with advanced solid tumors that combining the pegylated IL2 bempegaldesleukin with an anti-PD-1 mAb is safe, with an overall response rate of 59.5%. This compelling clinical activity is supported by th...

journal_title：Cancer discovery

authors： Rouanne M,Zitvogel L,Marabelle A

更新日期：2020-08-01 00:00:00

abstract：:According to the final analysis of CLEOPATRA, first-line treatment with pertuzumab plus trastuzumab and docetaxel significantly improves overall survival for patients with HER2-positive metastatic breast cancer. As such, dual HER2 blockade plus chemotherapy should be the standard of care in this setting, researchers s...

journal_title：Cancer discovery

authors：

更新日期：2014-12-01 00:00:00

abstract：:Amgen's novel small-molecule inhibitor AMG 510 has become the first drug to successfully target a KRAS mutation in patients, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRASG1...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:Adding entinostat to exemestane improves survival in women with ER(+) advanced breast cancer. ...

journal_title：Cancer discovery

authors：

更新日期：2013-07-01 00:00:00

abstract：:Residual acute myeloid leukemia (AML) cells required bone marrow stromal cell-derived aspartate. ...

journal_title：Cancer discovery

authors：

更新日期：2020-10-01 00:00:00

abstract：:Even in diffuse large B-cell lymphoma (DLBCL), a cancer of professional antigen-presenting cells, response rates to immune checkpoint blockade therapy have been limited. One reason for DLBCL immune evasion is epigenetic repression instead of activation of the antigen-presenting MHC-a dissection of mechanisms underlyin...

journal_title：Cancer discovery

authors： Velcheti V,Wong KK,Saunthararajah Y

更新日期：2019-04-01 00:00:00

abstract：:A report from the American Cancer Society reveals that colorectal cancer in people younger than 50 continues to increase, a trend that has spread to the 50-to-64 age group for the first time. Multiple lines of evidence indicate that obesity, often pinpointed as the cause, is not the only contributor. ...

journal_title：Cancer discovery

authors：

更新日期：2020-06-01 00:00:00